Literature DB >> 8818337

Effects of cytochrome P450 inhibitors on EDHF-mediated relaxation in the rat hepatic artery.

P M Zygmunt1, G Edwards, A H Weston, S C Davis, E D Högestätt.   

Abstract

1. The possibility that the endothelium-derived hyperpolarising factor (EDHF) in the rat hepatic artery is a cytochrome P450 mono-oxygenase metabolite of arachidonic acid was examined in the present study. In this preparation, acetylcholine elicits EDHF-mediated relaxations in the presence of the nitric oxide (NO) synthase and cyclo-oxygenase inhibitors N omega-nitro-L-arginine (L-NOARG) and indomethacin, respectively. 2. 17-Octadecynoic acid (17-ODYA, 50 microM), a suicide-substrate inhibitor of the cytochrome P450 mono-oxygenases responsible for the production of 5,6-, 8,9-, 11,12- and 14,15-epoxyeicosatrienoic acids (EETs), had no effect on acetylcholine-induced relaxations in the presence of L-NOARG (0.3 mM) plus indomethacin (10 microM). Furthermore, 5,6-, 8,9-, 11,12- and 14,15- EETs failed to relax arteries without endothelium in the presence of L-NOARG plus indomethacin. 3. Proadifen and clotrimazole, which are inhibitors of several isoforms of cytochrome P450 mono-oxygenases, inhibited acetylcholine-induced relaxations in the presence of L-NOARG plus indomethacin. The concentration of acetylcholine which caused half-maximal relaxation was about 3 and 30 times higher in the presence than in the absence of clotrimazole (3 microM) and proadifen (10 microM), respectively. The maximal relaxation was reduced by proadifen but not by clotrimazole. Proadifen (10 microM) also inhibited acetylcholine-induced hyperpolarization in the presence of L-NOARG plus indomethacin. 4. In the presence of 30 mM K+ plus indomethacin (10 microM), acetylcholine induced an L-NOARG-sensitive relaxation mediated via release of NO. Under these conditions, proadifen (10 microM) shifted the acetylcholine concentration-response curve 6 fold to the right without affecting the maximal relaxation. Clotrimazole (3 microM) was without effect on these responses. The relaxant actions of the NO donor, 3-morpholino-sydnonimine, were unaffected by proadifen (10 microM). 5. The relaxant effects of the opener of ATP-sensitive potassium channels, levcromakalim, were abolished by proadifen (10 microM) and strongly attenuated by clotrimazole (3 microM). Proadifen (10 microM) also abolished the hyperpolarization induced by levcromakalim (1 microM). 6. The lack of effect of 17-ODYA on relaxations mediated by EDHF, together with the failure of extracellularly-applied EETs to produce relaxation, collectively suggest that EDHF is not an EET in the rat hepatic artery. It seems likely that inhibition of ion channels in the smooth muscle rather than reduced EDHF formation in the endothelium offers a better explanation for the actions of the cytochrome P450 inhibitors proadifen and clotrimazole.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818337      PMCID: PMC1909609          DOI: 10.1111/j.1476-5381.1996.tb15517.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Selective blockade of potassium-induced contractions of aortic strips by beta-diethylaminoethyl-diphenylpropylacetate (SKF 525A).

Authors:  S Kalsner; M Nickerson; G N Boyd
Journal:  J Pharmacol Exp Ther       Date:  1970-09       Impact factor: 4.030

2.  Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels.

Authors:  E D Högestätt; K E Andersson; L Edvinsson
Journal:  Acta Physiol Scand       Date:  1983-01

3.  The interaction of amine local anaesthetics with muscarinic receptors.

Authors:  W J Taylor; A Wolf; J M Young
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

4.  Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery.

Authors:  C Corriu; M Félétou; E Canet; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Calcium antagonists and contractile responses in rat vas deferens and guinea pig ileal smooth muscle.

Authors:  C R Triggle; V C Swamy; D J Triggle
Journal:  Can J Physiol Pharmacol       Date:  1979-08       Impact factor: 2.273

6.  Substance P-induced relaxation and hyperpolarization in human cerebral arteries.

Authors:  J Petersson; P M Zygmunt; L Brandt; E D Högestätt
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals.

Authors:  M Hecker; A T Bara; J Bauersachs; R Busse
Journal:  J Physiol       Date:  1994-12-01       Impact factor: 5.182

8.  Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids.

Authors:  S Shak; N O Reich; I M Goldstein; P R Ortiz de Montellano
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

9.  Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid.

Authors:  S Hu; H S Kim
Journal:  Eur J Pharmacol       Date:  1993-01-12       Impact factor: 4.432

10.  Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery.

Authors:  P M Zygmunt; E D Högestätt
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more
  17 in total

1.  Bradykinin attenuates the [Ca(2+)](i) response to angiotensin II of renal juxtamedullary efferent arterioles via an EDHF.

Authors:  J Marchetti; F Praddaude; R Rajerison; J L Ader; F Alhenc-Gelas
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  Effects of inhibitors of small- and intermediate-conductance calcium-activated potassium channels, inwardly-rectifying potassium channels and Na(+)/K(+) ATPase on EDHF relaxations in the rat hepatic artery.

Authors:  D A Andersson; P M Zygmunt; P Movahed; T L Andersson; E D Högestätt
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women.

Authors:  Louise C Kenny; Philip N Baker; David A Kendall; Michael D Randall; William R Dunn
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 4.  Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses.

Authors:  Cor de Wit; Tudor M Griffith
Journal:  Pflugers Arch       Date:  2010-04-09       Impact factor: 3.657

5.  Effects of cytochrome P450 inhibitors on potassium currents and mechanical activity in rat portal vein.

Authors:  G Edwards; P M Zygmunt; E D Högestätt; A H Weston
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

6.  Apamin-sensitive, non-nitric oxide (NO) endothelium-dependent relaxations to bradykinin in the bovine isolated coronary artery: no role for cytochrome P450 and K+.

Authors:  G R Drummond; S Selemidis; T M Cocks
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Evidence against the involvement of cytochrome P450 metabolites in endothelium-dependent hyperpolarization of the rat main mesenteric artery.

Authors:  B Vanheel; J Van de Voorde
Journal:  J Physiol       Date:  1997-06-01       Impact factor: 5.182

8.  Mechanisms of nitric oxide-independent relaxations induced by carbachol and acetylcholine in rat isolated renal arteries.

Authors:  F Jiang; C G Li; M J Rand
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 9.  Epoxygenase metabolites. Epithelial and vascular actions.

Authors:  J D Imig
Journal:  Mol Biotechnol       Date:  2000-11       Impact factor: 2.695

10.  Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels.

Authors:  H Dong; Y Jiang; W C Cole; C R Triggle
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.